Tat-braftide 

Tat-braftide is a peptide inhibitor designed to block the dimerization of BRAF, thereby inhibiting its kinase activity. The destruction of BRAF dimer by Tat-braftide makes BRAF protein more susceptible to proteasome degradation, directly inhibits the activity of BRAF kinase, and reduces the activation of MAPK signaling pathway. Tat-braftide can be used for the role of RAF kinase in MAPK signaling pathway and for the study of BRAF mutant cancers^[1].

2992.56

C₁₂₈H₂₂₇N₅₁O₃₀S

Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Gln-{X}-Thr-Arg-His-Val-Asn-Ile-Leu-Leu-Phe-Met X=-NH-CH2-CH2-O-CH2-CH2-O-CH2-C=O-

GRKKRRQRRR-{X}-TRHVNILLFM X=-NH-CH2-CH2-O-CH2-CH2-O-CH2-C=O-

O=C(CN)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N[C@H](C(NCCOCCOCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CCSC)=O)CC2=CC=CC=C2)=O)CC(C)C)=O)CC(C)C)=O)[C@H](CC)C)=O)CC(N)=O)=O)C(C)C)=O)CC3=CNC=N3)=O)CCCNC(N)=N)=O)[C@@H](C)O)=O)=O)CCC(N)=O)=O)CCC1)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCCCN)=O)CCCCN)=O)CCCNC(N)=N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gunderwala A Y, et al. Development of allosteric BRAF peptide inhibitors targeting the dimer interface of BRAF[J]. ACS chemical biology, 2019, 14(7): 1471-1480.  [Content Brief]